SCHEDULE: Baillie Gifford Discloses 4.9% Stake in Ginkgo Bioworks

Baillie Gifford & Co. reported a 4.9% beneficial ownership stake in Ginkgo Bioworks Holdings, Inc.'s Class A Common Stock as of December 31, 2025.

Summary

• Baillie Gifford & Co., an investment adviser based in the United Kingdom, reported beneficial ownership of 2,391,649 shares of Ginkgo Bioworks Holdings, Inc.'s Class A Common Stock.
• This ownership represents 4.9% of the Class A Common Stock outstanding.
• Baillie Gifford & Co. holds sole voting power and sole dispositive power over all 2,391,649 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure, as Schedule 13G filings primarily report passive ownership stakes and do not typically contain performance-related information or forward-looking statements about the issuer.

Positives

• Baillie Gifford & Co., a significant institutional investor, maintains a 4.9% beneficial ownership stake in Ginkgo Bioworks Holdings, Inc., which may be interpreted as a continued vote of confidence in the company.

Negatives

• The filing does not contain information that would be categorized as negatives regarding the issuer's operational performance or financial outlook.

Risks

• The filing does not contain information regarding specific risks related to Ginkgo Bioworks Holdings, Inc.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor confidence.

Key Dates

Keywords

Ginkgo Bioworks, Baillie Gifford, Class A Common Stock, SEC Filing, Schedule 13G, Beneficial Ownership, Investment Adviser, Biotechnology, Synthetic Biology